A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase III multi-center, double-masked, vehicle-controlled, randomized, parallel
group study evaluating the efficacy, safety and tolerability of EBI-005 as compared to
vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to
severe allergic conjunctivitis (AC) three times daily for 4 weeks.
Approximately 250 subjects at approximately 8 centers in the US will be screened and enrolled
into the study.